Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing Haduvio (oral nalbuphine ER) for chronic pruritus (severe itching) in rare diseases. The company's lead indication is pruritic conditions associated with chronic kidney disease (CKD-aP), with additional development in primary biliary cholangitis and other rare dermatologic conditions. With no revenue and a $1.3B market cap, the stock trades on clinical trial outcomes, regulatory milestones, and partnership potential.
Trevi operates as a pure-play clinical development company burning cash to advance Haduvio through Phase 3 trials and regulatory approval. The business model depends on: (1) successful clinical trial readouts demonstrating statistically significant reduction in pruritus intensity, (2) FDA approval for orphan or breakthrough therapy designation enabling premium pricing ($50K-$150K annually per patient estimated for rare disease treatments), (3) either building commercial infrastructure or partnering with larger pharma for distribution. The company's competitive advantage lies in targeting underserved rare disease populations with high unmet medical need where existing antihistamines and topical treatments fail, potentially commanding pricing power. Current cash runway extends into 2027-2028 based on $139M cash position and quarterly burn rate of approximately $10-12M.
Phase 3 clinical trial data releases for Haduvio in CKD-associated pruritus (primary endpoint: change in Worst Itching Intensity Numerical Rating Scale)
FDA regulatory milestone announcements including Breakthrough Therapy Designation, New Drug Application (NDA) submission acceptance, and PDUFA target action dates
Partnership or licensing deal announcements with larger pharmaceutical companies for commercialization rights
Cash runway updates and equity financing announcements (dilution concerns vs. extended operational runway)
Competitive clinical data from alternative pruritus treatments or kappa opioid receptor agonists
Expansion into additional indications beyond CKD-aP (primary biliary cholangitis, atopic dermatitis)
Binary clinical trial risk: Phase 3 failure in CKD-associated pruritus would likely result in 70-90% stock decline given single-asset focus. Haduvio must demonstrate statistically significant efficacy on primary endpoints with acceptable safety profile.
FDA regulatory risk: Even with positive trial data, FDA may require additional studies, impose restrictive labeling, or delay approval. Rare disease approvals face heightened scrutiny on durability of effect and real-world evidence.
Reimbursement and market access risk: Payers increasingly challenge high-cost rare disease therapies. Medicare/Medicaid coverage decisions and prior authorization requirements could limit commercial uptake even post-approval.
Patent cliff and exclusivity: Composition of matter patents and regulatory exclusivity windows determine commercial runway. Generic or biosimilar competition post-exclusivity would erode pricing power.
Alternative mechanism competition: Other companies developing kappa opioid receptor agonists or novel anti-pruritic mechanisms could reach market first or demonstrate superior efficacy, commoditizing the indication.
Large pharma entry: Major pharmaceutical companies with established nephrology/dermatology franchises could in-license or develop competing assets with superior commercial infrastructure and payer relationships.
Off-label competition: Existing approved therapies used off-label for pruritus (gabapentin, pregabalin, UV phototherapy) create low-cost alternatives that payers may prefer despite inferior efficacy.
Equity dilution risk: With negative operating cash flow and no debt capacity, future capital needs will require equity raises. At current $10-12M quarterly burn, additional financing likely needed in 2027-2028, potentially at dilutive valuations if clinical data disappoints.
Clinical trial cost overruns: Phase 3 trials can experience enrollment delays, protocol amendments, or expanded safety monitoring requirements that increase cash burn beyond projections, accelerating need for capital.
Going concern risk if unable to access capital markets: While current 21.93x current ratio provides cushion, sustained equity market closure for biotechs could force asset sales, unfavorable partnerships, or bankruptcy if cash depletes before commercialization.
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending follows predetermined clinical trial protocols regardless of economic conditions. However, capital markets access for financing is cyclically sensitive: risk appetite for speculative biotech equity declines during recessions, potentially constraining ability to raise capital at favorable valuations. Patient enrollment in trials may see modest impacts during severe downturns if healthcare access deteriorates.
Rising interest rates create significant headwinds for pre-revenue biotechs through multiple channels: (1) higher discount rates compress NPV of distant future cash flows, disproportionately impacting companies 3-5+ years from commercialization, (2) risk-free rate competition makes speculative growth equity less attractive relative to bonds, (3) increased financing costs if debt is utilized, though Trevi currently carries zero debt. The 10-year Treasury yield serves as the primary valuation anchor - biotech multiples historically contract 15-25% when 10Y yields rise 100bps. Conversely, falling rates expand valuation multiples for long-duration growth assets.
Minimal direct credit exposure as the company has no debt and operates with a 21.93x current ratio indicating strong liquidity. However, credit market conditions indirectly impact capital raising ability: widening high-yield spreads signal risk-off sentiment that typically closes IPO/follow-on windows for speculative biotechs. Tightening credit can also pressure potential pharma partners' M&A budgets, reducing partnership valuations.
growth/speculative - Attracts biotech-specialized investors, venture capital crossover funds, and momentum traders seeking asymmetric risk/reward from binary clinical catalysts. The 123.9% one-year return and 39.8% six-month return indicate strong momentum following, likely driven by positive clinical updates or regulatory progress. Not suitable for value or income investors given negative earnings, no dividend, and binary event risk. Institutional ownership likely concentrated among healthcare-focused hedge funds and biotech mutual funds willing to underwrite clinical trial risk.
high - Clinical-stage single-asset biotechs exhibit extreme volatility with 20-40% single-day moves common around data releases. The -7.3% three-month return against +39.8% six-month return demonstrates choppy trading patterns. Implied volatility typically spikes 50-100% ahead of Phase 3 readouts. Beta likely exceeds 2.0x relative to broader market, with idiosyncratic risk dominating systematic risk. Options market typically prices 60-80% implied volatility for near-term contracts around catalyst dates.
